Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 21.

Cozzi-Lepri, A; Zangerle, R; Machala, L; Zilmer, K; Ristola, M; Pradier, C; Kirk, O; Sambatakou, H; Fätkenheuer, G; Yust, I; Schmid, P; Gottfredsson, M; Khromova, I; Jilich, D; Flisiak, R; Smidt, J; Rozentale, B; Radoi, R; Losso, M H; Lundgren, J D; Mocroft, A; EuroSIDA Study Group (2017). Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens. HIV Medicine:Epub ahead of print.

Shepherd, L; Borges, Áh; Ledergerber, B; Domingo, P; Castagna, A; Rockstroh, J; Knysz, B; Tomazic, J; Karpov, I; Kirk, O; Lundgren, J; Mocroft, A (2016). Infection-related and -unrelated malignancies, HIV and the aging population. HIV Medicine, 17(8):590-600.

Grint, D; Peters, L; Reekie, J; Soriano, V; Kirk, O; Knysz, B; Suetnov, O; Lazzarin, A; Ledergerber, B; Rockstroh, J K; Mocroft, A (2013). Stability of hepatitis C virus (HCV) RNA levels among interferon-naïve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy. HIV Medicine, 14(6):370-378.

Mocroft, A; Furrer, H J; Miro, J M; Reiss, P; Mussini, C; Kirk, O; Abgrall, S; Ayayi, S; Bartmeyer, B; Braun, D; Castagna, A; d'Arminio Monforte, A; Gazzard, B; Gutierrez, F; Hurtado, I; Jansen, K; Meyer, L; Muñoz, P; Obel, N; Soler-Palacin, P; Papadopoulos, A; Raffi, F; Ramos, J T; Rockstroh, J K; Salmon, D; Torti, C; Warszawski, J; de Wit, S; Zangerle, R; Fabre-Colin, C; Kjaer, J; Chene, G; Grarup, J; Lundgren, J D (2013). The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era. Clinical Infectious Diseases, 57(7):1038-1047.

Mocroft, A; Phillips, A; Gatell, J; Horban, A; Ledergerber, B; Zilmer, K; Jevtovic, D; Maltez, F; Kirk, O; Lundgren, J (2012). CD4 count and viral load specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use. Journal of the International Aids Society, 15(6):18191.

Kowalska, J D; Reekie, J; Mocroft, A; Reiss, P; Ledergerber, B; Gatell, J; D'Arminio Monforte, A; Phillips, A; Lundgren, J D; Kirk, O (2012). Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy. AIDS, 26(3):315-323.

Murray, M; Hogg, R S; Lima, V D; May, M T; Moore, D M; Abgrall, S; Bruyand, M; D'Arminio Monforte, A; Tural, C; Gill, M J; Harris, R J; Reiss, P; Justice, A; Kirk, O; Saag, M; Smith, C J; Weber, R; Rockstroh, J; Khaykin, P; Sterne, J A C (2012). The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis. HIV Medicine, 13(2):89-97.

Kowalska, J D; Mocroft, A; Ledergerber, B; Florence, E; Ristola, M; Begovac, J; Sambatakou, H; Pedersen, C; Lundgren, J D; Kirk, O (2011). A standardized algorithm for determining the underlying cause of death in HIV infection as AIDS or non-AIDS related: results from the EuroSIDA study. HIV Clinical Trials, 12(2):109-117.

Petoumenos, K; Worm, S; Reiss, P; de Wit, S; D'Arminio Monforte, A; Sabin, C; Friis-Møller, N; Weber, R; Mercie, P; Pradier, C; El-Sadr, W; Kirk, O; Lundgren, J; Law, M (2011). Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study. HIV Medicine, 12(7):412-421.

Mocroft, A; Phillips, A N; Ledergerber, B; Smith, C; Bogner, J R; Lacombe, K; Wiercinska-Drapalo, A; Reiss, P; Kirk, O; Lundgren, J D (2010). Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy. Antiviral Therapy, 15(4):563-570.

Mocroft, A; Kirk, O; Reiss, P; De Wit, S; Sedlacek, D; Beniowski, M; Gatell, J; Phillips, A N; Ledergerber, B; Lundgren, J D (2010). Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS, 24(11):1667-1678.

Smith, C J; Sabin, C A; Lundgren, J D; Thiebaut, R; Weber, R; Law, M; D'Arminio Monforte, A; Kirk, O; Friis-Moller, N; Phillips, A; Reiss, P; El-Sadr, W; Pradier, C; Worm, S W (2010). Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study. AIDS, 24(10):1537-1548.

Weber, R; Sabin, C; Reiss, P; De Wit, S; Worm, S W; Law, M; Dabis, F; D'Arminio Monforte, A; Fontas, E; El-Sadr, W; Kirk, O; Rickenbach, M; Phillips, A; Ledergerber, B; Lundgren, J (2010). HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D cohort study. Antiviral Therapy, 15(8):1077-1086.

Friis-Møller, N; Thiebaut, R; Reiss, P; Weber, R; Monforte, A D; De Wit, S; El-Sadr, W; Fontas, E; Worm, S W; Kirk, O; Phillips, A; Sabin, C A; Lundgren, J D; Law, M G (2010). Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. European Journal of Cardiovascular Prevention and Rehabilitation, 17(5):491-501.

Worm, S W; Sabin, C; Weber, R; Reiss, P; El-Sadr, W; Dabis, F; De Wit, S; Law, M; D'Arminio Monforte, A; Friis-Møller, N; Kirk, O; Fontas, E; Weller, I; Phillips, A; Lundgren, J (2010). Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. Journal of Infectious Diseases, 201(3):318-330.

Mocroft, A; Reiss, P; Gasiorowski, J; Ledergerber, B; Kowalska, J; Chiesi, A; Gatell, J; Rakhmanova, A; Johnson, M; Kirk, O; Lundgren, J (2010). Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. Journal of Acquired Immune Deficiency Syndrome, 55(2):262-270.

Worm, S W; De Wit, S; Weber, R; Sabin, C A; Reiss, P; El-Sadr, W; Monforte, A D; Kirk, O; Fontas, E; Dabis, F; Law, M G; Lundgren, J D; Friis-Møller, N (2009). Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study). Circulation, 119(6):805-811.

D'Arminio Monforte, A; Abramson, D; Pradier, C; Weber, R; Reiss, P; Bonnet, F; Kirk, O; Law, M; De Wit, S; Friis-Møller, N; Phillips, A N; Sabin, C A; Lundgren, J D (2008). HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS, 22(16):2143-2153.

Sabin, C A; d'Arminio Monforte, A; Friis-Moller, N; Weber, R; El-Sadr, W M; Reiss, P; Kirk, O; Mercie, P; Law, M G; De Wit, S; Pradier, C; Phillips, A N; Lundgren, J D (2008). Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction. Clinical Infectious Diseases, 46(7):1101-1110.

Podlekareva, D; Mocroft, A; Kirk, O; Reiss, P; Aldins, P; Katlama, C; Kovari, H; Stellbrink, H J; D'Arminio Monforte, A; Lundgren, J D (2008). Fungal infection as a risk factor for HIV disease progression among patients with a CD4 count above 200/microl in the era of cART. Scandinavian Journal of Infectious Diseases, 40(11):908-913.

Sabin, C A; Worm, S W; Weber, R; Reiss, P; El-Sadr, W; Dabis, F; De Wit, S; Law, M; D'Arminio Monforte, A; Friis-Møller, N; Kirk, O; Pradier, C; Weller, I; Phillips, A N; Lundgren, J D; D:A:D Study Group (2008). Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet, 371(9622):1417-1426.

This list was generated on Sat Nov 18 20:20:25 2017 CET.